Skip to main content
Journal cover image

High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa.

Publication ,  Journal Article
Jiang, SW; Kwock, JT; Liu, B; Petty, AJ; Zhao, AT; Green, CL; Jaleel, T
Published in: Br J Dermatol
September 2022

In this case series, ustekinumab therapy demonstrated efficacy in some patients with severe hidradenitis suppurativa previously treated with adalimumab and/or infliximab. Larger prospective studies are needed to evaluate ustekinumab as a treatment option for recalcitrant hidradenitis suppurativa.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Br J Dermatol

DOI

EISSN

1365-2133

Publication Date

September 2022

Volume

187

Issue

3

Start / End Page

417 / 419

Location

England

Related Subject Headings

  • Ustekinumab
  • Infliximab
  • Humans
  • Hidradenitis Suppurativa
  • Dermatology & Venereal Diseases
  • Dermatologic Agents
  • Adalimumab
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jiang, S. W., Kwock, J. T., Liu, B., Petty, A. J., Zhao, A. T., Green, C. L., & Jaleel, T. (2022). High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa. Br J Dermatol, 187(3), 417–419. https://doi.org/10.1111/bjd.21066
Jiang, Simon W., Jeffery T. Kwock, Beiyu Liu, Amy J. Petty, Aaron T. Zhao, Cynthia L. Green, and Tarannum Jaleel. “High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa.Br J Dermatol 187, no. 3 (September 2022): 417–19. https://doi.org/10.1111/bjd.21066.
Jiang SW, Kwock JT, Liu B, Petty AJ, Zhao AT, Green CL, et al. High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa. Br J Dermatol. 2022 Sep;187(3):417–9.
Jiang, Simon W., et al. “High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa.Br J Dermatol, vol. 187, no. 3, Sept. 2022, pp. 417–19. Pubmed, doi:10.1111/bjd.21066.
Jiang SW, Kwock JT, Liu B, Petty AJ, Zhao AT, Green CL, Jaleel T. High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa. Br J Dermatol. 2022 Sep;187(3):417–419.
Journal cover image

Published In

Br J Dermatol

DOI

EISSN

1365-2133

Publication Date

September 2022

Volume

187

Issue

3

Start / End Page

417 / 419

Location

England

Related Subject Headings

  • Ustekinumab
  • Infliximab
  • Humans
  • Hidradenitis Suppurativa
  • Dermatology & Venereal Diseases
  • Dermatologic Agents
  • Adalimumab
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences